GlassScriptPhysician profile
Gary Lee Pattee
NPI 1396794749
$131,649.63
in general payments reported to CMS, 2019-2025
92 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,941 · 2020: $5,405 · 2021: $17K · 2022: $16K · 2023: $64K · 2024: $18K · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $43K · Travel and Lodging: $20K · Food and Beverage: $9,081 · Consulting Fee: $8,125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,063 · Education: $74.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $43,200.84 |
| Travel and Lodging | $20,328.77 |
| Food and Beverage | $9,080.52 |
| Consulting Fee | $8,125.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,062.50 |
| Education | $74.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $58,974.68 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $40,327.57 | 2019-2025 | Radicava, Radicava Ors |
| Biogen, INC. | $8,437.07 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,292.00 | 2020-2021 | |
| Zambon USA LTD. | $2,792.86 | 2023 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $2,086.42 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $2,062.67 | 2019-2025 | Firdapse |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $959.50 | 2019 | |
| Ucb, INC. | $900.94 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $801.35 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $679.96 | 2019-2025 | |
| Genzyme Corporation | $555.44 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $441.93 | 2019-2025 | Ultomiris |
| Csl Behring | $436.76 | 2019-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $430.38 | 2019-2022 |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $383.76 | 2019-2025 | |
| Lilly USA, LLC | $270.77 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Celgene Corporation | $261.08 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $259.68 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $254.80 | 2020-2025 | |
| Genentech USA, INC. | $253.23 | 2019-2023 | Evrysdi, Ocrevus |
| Argenx US, INC. | $245.97 | 2022-2025 | Vyvgart |
| Acadia Pharmaceuticals INC | $236.47 | 2020-2025 | Nuplazid |
| Neurelis, INC. | $202.57 | 2020-2024 | Valtoco |
| Amgen INC. | $193.36 | 2019-2022 | |
| Greenwich Biosciences, INC. | $160.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $160.68 | 2023-2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $152.39 | 2020-2024 | Nourianz |
| Mdd US Operations, LLC | $145.84 | 2021-2024 | Gocovri, Gocovri |
| Lundbeck LLC | $145.59 | 2021-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $143.30 | 2023-2025 | Hyqvia, Gammagard |
| E.R. Squibb & Sons, L.L.C. | $137.42 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $133.58 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amicus Therapeutics, INC. | $122.66 | 2024-2025 | Pombiliti, Opfolda |
| Pfizer INC. | $113.65 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $107.09 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $104.77 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $98.88 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $94.11 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $93.89 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $88.39 | 2025 | |
| Alnylam Pharmaceuticals INC. | $84.79 | 2022-2023 | Onpattro |
| Jazz Pharmaceuticals INC. | $81.52 | 2021-2025 | |
| Octapharma USA, INC. | $73.91 | 2022-2025 | Octagam Immune Globulin (Human) |
| Sunovion Pharmaceuticals INC. | $73.83 | 2020-2022 | |
| Acorda Therapeutics, INC | $73.48 | 2019-2021 | |
| Horizon Therapeutics Plc | $71.56 | 2021-2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $68.72 | 2021 | |
| Merz Pharmaceuticals, LLC | $65.42 | 2025 | Xeomin, Inbrija |
| Boston Scientific Corporation | $63.53 | 2023 | Vercise |
| Banner Life Sciences, LLC | $63.09 | 2023-2024 | |
| Sarepta Therapeutics, INC. | $63.00 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $61.96 | 2024-2025 | Ponvory |
| Impel Pharmaceuticals INC. | $58.79 | 2022-2023 | Trudhesa |
| Allergan, INC. | $58.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $57.71 | 2024-2025 | Wainua, Brilinta |
| Otsuka America Pharmaceutical, INC. | $56.12 | 2023-2024 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $53.01 | 2022 | |
| Arbor Pharmaceuticals, INC. | $49.72 | 2020-2022 | |
| Ge Healthcare | $46.32 | 2020-2023 | |
| Grt US Holding, INC. | $44.86 | 2021-2022 | |
| Chiesi USA, INC. | $41.78 | 2019-2020 | |
| Tg Therapeutics, INC. | $40.11 | 2023-2024 | |
| Almatica Pharma LLC | $38.49 | 2021-2023 | Gralise |
| Medtronic, INC. | $37.31 | 2021-2025 | Linq II |
| Axsome Therapeutics, INC. | $35.79 | 2023 | Sunosi |
| Abbott Laboratories | $34.25 | 2022-2024 | Infinity |
| Azurity Pharmaceuticals, INC. | $32.56 | 2023-2024 | Horizant, Horizant |
| Cycle Pharmaceuticals INC | $31.15 | 2025 | Tascenso Odt |
| Amneal Pharmaceuticals LLC | $31.05 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $30.38 | 2022-2023 | |
| Itf Therapeutics LLC | $30.37 | 2025 | |
| Zogenix INC. | $27.68 | 2021 | |
| Averitas Pharma INC. | $25.63 | 2023 | Qutenza |
| Xeris Pharmaceuticals, INC. | $19.70 | 2025 | Keveyis |
| Upsher-Smith Laboratories LLC | $19.41 | 2019 | |
| Avion Pharmaceuticals | $17.64 | 2022 | |
| Mirum Pharmaceuticals, INC. | $17.60 | 2024 | Cholbam |
| Genentech, INC. | $17.46 | 2020 | |
| Hospira, INC. | $16.67 | 2024 | |
| Ns Pharma, INC. | $16.23 | 2021 | |
| Sumitomo Pharma America, INC. | $15.78 | 2023 | Aptiom |
| Vertical Pharmaceuticals, LLC | $14.31 | 2020 | |
| Medtronic Vascular, INC. | $12.66 | 2019 | |
| Promius Pharma LLC | $11.94 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.39 | 2019 | |
| Edw Pharma, INC. | $8.50 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,729.04 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pattee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.